In Vitro Preclinical Cardiac Assessment of Tolterodine and Terodiline: Multiple Factors Predict the Clinical Experience
暂无分享,去创建一个
Gary A Gintant | Zhi Su | G. Gintant | Ruth L. Martin | B. Cox | Ruth L Martin | Bryan F Cox | Z. Su | J. Limberis | Marlon D Cowart | James T Limberis | Jason D Palmatier | M. Cowart | Jason Palmatier
[1] Serge Richard,et al. Prediction of the risk of Torsade de Pointes using the model of isolated canine Purkinje fibres , 2005, British journal of pharmacology.
[2] L. Nilvebrant. Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. , 2002, Pharmacology & toxicology.
[3] Martin Borggrefe,et al. Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.
[4] P. Ekelund,et al. Single- and multiple-dose pharmacokinetics of terodiline in geriatric patients , 1988, European Journal of Clinical Pharmacology.
[5] J. Gabrielsson,et al. Concomitant single-dose and multiple-dose pharmacokinetics of terodiline in man, with a note on its enantiomers and major metabolites. , 1995, Pharmacology & toxicology.
[6] M. Viitasalo,et al. Effects of Epinephrine on Right Ventricular Monophasic Action Potentials in the LQT1 Versus LQT2 Form of Long QT Syndrome: Preferential Enhancement of “Triangulation” in LQT1 , 2005, Pacing and clinical electrophysiology : PACE.
[7] J. Hancox,et al. Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine , 2002, British journal of pharmacology.
[8] J. Malone-lee,et al. Tolterodine: A Safe and Effective Treatment for Older Patients with Overactive Bladder , 2001, Journal of the American Geriatrics Society.
[9] D. Zipes,et al. In Vivo and In Vitro Electrophysiologic Effects of Terodiline on Dog Myocardium , 1995, Journal of cardiovascular electrophysiology.
[10] L. Burrows,et al. Benefit-Risk Assessment of Tolterodine in the Treatment of Overactive Bladder in Adults , 2004, Drug safety.
[11] T. Ogura,et al. Action potentials, contraction, and membrane currents in guinea pig ventricular preparations treated with the antispasmodic agent terodiline. , 1999, The Journal of pharmacology and experimental therapeutics.
[12] F. Lang,et al. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action , 1998, British journal of pharmacology.
[13] M. Jiang,et al. Use-dependent 'agonist' effect of azimilide on the HERG channel. , 1999, The Journal of pharmacology and experimental therapeutics.
[14] T. Ogura,et al. Inhibition of the rapid component of the delayed‐rectifier K+ current by therapeutic concentrations of the antispasmodic agent terodiline , 1998, British journal of pharmacology.
[15] D. Wyse,et al. Propafenone‐Induced Torsade de Pointes: Cross‐Reactivity with Quinidine , 1991, Pacing and clinical electrophysiology : PACE.
[16] G. Gintant,et al. Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. , 2004, Journal of molecular and cellular cardiology.
[17] R. Ruffolo,et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. , 1996, The Journal of pharmacology and experimental therapeutics.
[18] A. Camm,et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.
[19] J. Cowan,et al. Torsades de pointes ventricular tachycardia and terodiline , 1991, The Lancet.
[20] R. Campbell,et al. Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. , 1995, British heart journal.
[21] Hua-rong Lu,et al. Drug-induced long QT in isolated rabbit Purkinje fibers: importance of action potential duration, triangulation and early afterdepolarizations. , 2002, European journal of pharmacology.
[22] L. Shuba,et al. Differences in the effects of urinary incontinence agents S‐oxybutynin and terodiline on cardiac K+ currents and action potentials , 2000, British journal of pharmacology.
[23] Richard L. Page,et al. Effects of Azimilide on Heart Rate and ECG Conduction Intervals during Sinus Rhythm in Patients with a History of Atrial Fibrillation , 2002, Journal of clinical pharmacology.
[24] P. Hoffmann,et al. Blinded Test in Isolated Female Rabbit Heart Reliably Identifies Action Potential Duration Prolongation and Proarrhythmic Drugs: Importance of Triangulation, Reverse Use Dependence, and Instability , 2003, Journal of cardiovascular pharmacology.
[25] D. McTavish,et al. Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence. , 1990, Drugs.
[26] E. Rovner. Tolterodine for the treatment of overactive bladder: a review , 2005, Expert opinion on pharmacotherapy.
[27] G. Setterberg,et al. Tolerability and steady-state pharmacokinetics of terodiline and its main metabolites in elderly patients with urinary incontinence , 2004, European Journal of Clinical Pharmacology.
[28] G. Duker,et al. Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.
[29] R. Shah,et al. Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. , 2005, Heart rhythm.
[30] Jiesheng Kang,et al. Cardiac Ion Channel Effects of Tolterodine , 2004, Journal of Pharmacology and Experimental Therapeutics.
[31] K. Andersson. Clinical pharmacology of terodiline. , 1984, Scandinavian journal of urology and nephrology. Supplementum.
[32] P. Gozzi,et al. Serum protein binding of tolterodine and its major metabolites in humans and several animal species , 1999, Biopharmaceutics & drug disposition.
[33] A. A. Mcleod,et al. Torsades de pointes complicating treatment with terodiline. , 1991, BMJ.
[34] C. January,et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.
[35] Andersson Ke. Clinical pharmacology of terodiline. , 1984 .
[36] S. Shakir,et al. Safety Profile of Tolterodine as Used in General Practice in England , 2001, Drug safety.
[37] G. Gintant,et al. The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis , 2001, Journal of cardiovascular pharmacology.
[38] D. Stott,et al. Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval , 2004, European Journal of Clinical Pharmacology.
[39] D. Raunig,et al. The Relationship of Clinical QT Prolongation to Outcome in the Conscious Dog Using a Beat-to-Beat QT-RR Interval Assessment , 2002, Journal of Pharmacology and Experimental Therapeutics.
[40] Gary A Gintant,et al. The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block , 2004, Journal of cardiovascular pharmacology.
[41] C. January,et al. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.